Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-Week analysis from the RESIST-1 trial

Joseph Gathe, David A. Cooper, Charles Farthing, Dushyantha Jayaweera, Dorece Norris, Gerald Pierone, Corklin R. Steinhart, Benoit Trottier, Sharon L. Walmsley, Cassy Workman, Geoffrey Mukwaya, Veronika Kohlbrenner, Catherine Dohnanyi, Scott McCallister, Douglas Mayers

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


Background. Improved treatment options are needed for patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1). The nonpeptidic protease inhibitor tipranavir has demonstrated antiviral activity against many protease inhibitor-resistant HIV-1 isolates. The Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST-1) trial is an ongoing, open-label study comparing the efficacy and safety of ritonavir-boosted tipranavir (TPV/r) with an investigator-selected ritonavir-boosted comparator protease inhibitor (CPI/r) in treatment-experienced, HIV- 1-infected patients. Methods. Six hundred twenty antiretroviral-experienced patients were treated at 125 sites in North America and Australia. Before randomization, all patients underwent genotypic resistance testing, which investigators used to select a CPI/r and an optimized background regimen. Patients were randomized to receive TPV/r or CPI/r and were stratified on the basis of preselected protease inhibitor and enfuvirtide use. Treatment response was defined as a confirmed reduction in the HIV-1 load of ≥1 log10 less than the baseline level without treatment change at week 24. Results. Mean baseline HIV-1 loads and CD4+ cell counts were 4.74 log10 copies/mL and 164 cells/mm3, respectively. At week 24, a total of 41.5% of patients in the TPV/r arm and 22.3% in the CPI/r arm had a ≥1-log10 reduction in the HIV-1 load (intent-to-treat population; P < .0001). Mean increases in the CD4+ cell count of 54 and 24 cells/mm3 occurred in the TPV/r and CPI/r groups, respectively. Adverse events were slightly more common in the TPV/r group and included diarrhea, nausea, and vomiting. Elevations in alanine and aspartate aminotransferase levels and in cholesterol/triglyceride levels were more frequent in the TPV/r group. Conclusions. TPV/r demonstrated superior antiviral activity, compared with investigator-selected, ritonavir-boosted protease inhibitors, at week 24 in treatment-experienced patients with multidrug-resistant HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)1337-1346
Number of pages10
JournalClinical Infectious Diseases
Issue number10
StatePublished - Nov 15 2006

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-Week analysis from the RESIST-1 trial'. Together they form a unique fingerprint.

Cite this